Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06211036 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
A Phase 3 study of Small-cell Lung Cancer and Extensive-stage Small-cell Lung Cancer, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 563
- Enrollment target
- 20
- Study locations
NCT06211036 is a Phase 3 study of Small-cell Lung Cancer and Extensive-stage Small-cell Lung Cancer that is active but no longer recruiting, run by Amgen. The registered enrollment target is 563 participants, above the 225-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (150% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT06211036, a Phase 3 study of Small-cell Lung Cancer and Extensive-stage Small-cell Lung Cancer, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 563 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG Tarlatamab
Study Locations (20)
Georgia
- University Cancer and Blood Center LLC - Athens
- Emory University - Atlanta
- Northeast Georgia Medical Center - Gainesville
Minnesota
- Mayo Clinic - Rochester
- Allina Health System dba Allina Health Cancer Institute - Saint Paul
New Jersey
- Astera Cancer Care - East Brunswick
- Rutgers Cancer Institute of New Jersey - New Brunswick
North Carolina
- Duke University - Durham
- Wake Forest University Health Sciences - Winston-Salem
Alabama
- Infirmary Cancer Center - Mobile
California
- University of Southern California - Los Angeles
Connecticut
- Yale New Haven Hospital - New Haven
Illinois
- University of Illinois Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 563 participants |
| Start Date | 2024-06-05 |
| Est. Completion | 2028-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06211036
The ClinicalTrials.gov registry entry for NCT06211036 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 563 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 225-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (150% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT06211036 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Georgia, Minnesota, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06211036 about?
NCT06211036 is a clinical study titled "Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab". The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
What is the current status of trial NCT06211036?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 563 participants. The study started on 2024-06-05. Estimated completion is 2028-09-30.
What conditions does trial NCT06211036 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer.
What interventions are being tested in trial NCT06211036?
The interventions under investigation include: Durvalumab (DRUG), Tarlatamab (DRUG).
Who is sponsoring clinical trial NCT06211036?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06211036 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
RECRUITING · Phase 3
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
RECRUITING · Phase 3
-
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.